These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20847101)

  • 21. Improving the affinity of antigens for mutated antibodies by use of statistical molecular design.
    Mandrika I; Prusis P; Bergström J; Yahorava S; Wikberg JE
    J Pept Sci; 2008 Jul; 14(7):786-96. PubMed ID: 18200617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold.
    Lee CV; Liang WC; Dennis MS; Eigenbrot C; Sidhu SS; Fuh G
    J Mol Biol; 2004 Jul; 340(5):1073-93. PubMed ID: 15236968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
    Wu H; Nie Y; Huse WD; Watkins JD
    J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting molecular interactions and inducible complementarity: fragment docking of Fab-peptide complexes.
    Friedman AR; Roberts VA; Tainer JA
    Proteins; 1994 Sep; 20(1):15-24. PubMed ID: 7529922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Collagen type II is recognized by a pathogenic antibody through germline encoded structures.
    Böiers U; Lanig H; Sehnert B; Holmdahl R; Burkhardt H
    Eur J Immunol; 2008 Oct; 38(10):2784-95. PubMed ID: 18825755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide.
    Entzminger KC; Hyun JM; Pantazes RJ; Patterson-Orazem AC; Qerqez AN; Frye ZP; Hughes RA; Ellington AD; Lieberman RL; Maranas CD; Maynard JA
    Sci Rep; 2017 Aug; 7(1):10295. PubMed ID: 28860479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
    Julien JP; Bryson S; Nieva JL; Pai EF
    J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modelling.
    Hou S; Li B; Wang L; Qian W; Zhang D; Hong X; Wang H; Guo Y
    J Biochem; 2008 Jul; 144(1):115-20. PubMed ID: 18424812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling.
    Eigenbrot C; Randal M; Presta L; Carter P; Kossiakoff AA
    J Mol Biol; 1993 Feb; 229(4):969-95. PubMed ID: 8095303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RosettaAntibodyDesign (RAbD): A general framework for computational antibody design.
    Adolf-Bryfogle J; Kalyuzhniy O; Kubitz M; Weitzner BD; Hu X; Adachi Y; Schief WR; Dunbrack RL
    PLoS Comput Biol; 2018 Apr; 14(4):e1006112. PubMed ID: 29702641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.
    van den Beucken T; van Neer N; Sablon E; Desmet J; Celis L; Hoogenboom HR; Hufton SE
    J Mol Biol; 2001 Jul; 310(3):591-601. PubMed ID: 11439026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions.
    Perchiacca JM; Ladiwala AR; Bhattacharya M; Tessier PM
    Protein Eng Des Sel; 2012 Oct; 25(10):591-601. PubMed ID: 22843678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis.
    Vajdos FF; Adams CW; Breece TN; Presta LG; de Vos AM; Sidhu SS
    J Mol Biol; 2002 Jul; 320(2):415-28. PubMed ID: 12079396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.
    Finlay WJ; Cunningham O; Lambert MA; Darmanin-Sheehan A; Liu X; Fennell BJ; Mahon CM; Cummins E; Wade JM; O'Sullivan CM; Tan XY; Piche N; Pittman DD; Paulsen J; Tchistiakova L; Kodangattil S; Gill D; Hufton SE
    J Mol Biol; 2009 May; 388(3):541-58. PubMed ID: 19285987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code.
    Fellouse FA; Barthelemy PA; Kelley RF; Sidhu SS
    J Mol Biol; 2006 Mar; 357(1):100-14. PubMed ID: 16413576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
    Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
    Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A focused antibody library for improved hapten recognition.
    Persson H; Lantto J; Ohlin M
    J Mol Biol; 2006 Mar; 357(2):607-20. PubMed ID: 16445941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Display of somatostatin-related peptides in the complementarity determining regions of an antibody light chain.
    Simon PJ; Brogle KC; Wang B; Kyle DJ; Soltis DA
    Arch Biochem Biophys; 2005 Aug; 440(2):148-57. PubMed ID: 16051181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
    Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B
    Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OptMAVEn--a new framework for the de novo design of antibody variable region models targeting specific antigen epitopes.
    Li T; Pantazes RJ; Maranas CD
    PLoS One; 2014; 9(8):e105954. PubMed ID: 25153121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.